Summarized by Masters of Longevity from Longevity Technology.
Biogen will present long-term efficacy, safety and biomarker results at CTAD.
Key Takeaways
- Biogen will present 96-week efficacy and safety data.
- Researchers will report 76-week tau and amyloid PET results.
- Presentations were to include ARIA safety and recruitment analyses.
